Compass Therapeutics Announces Preclinical Data on Lead Antibody Program and NK Cell Engager Platform to be Presented at the Society for Immunotherapy of Cancer Annual Meeting
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, today announced that preclinical data on CTX-471, a fully human monoclonal antibody that potently induces immune-mediated destruction of solid tumors, will be presented at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting, which is being held this week in Washington, D.C. Preclinical data from the company’s novel NK cell engager platform will also be presented.
“To our knowledge, CTX-471’s preclinical efficacy as a monotherapy in a very large tumor model is unprecedented for an immuno-oncology antibody. These data support our plans to advance our lead therapeutic candidate into the clinic in the first quarter of 2019,” said Thomas Schuetz, M.D., Ph.D., the company’s co-founder and chief executive officer. “In addition, the data on our NK cell engager platform are very exciting. Our preclinical results underscore the power of our StitchMabs™ technology and our empirical approach to identifying novel combinations of therapeutic candidates that can engage the innate and adaptive immune system in unique and novel ways to eradicate tumors.”Back to News